Meninges hemangiopericytoma

Summary

Meninges hemangiopericytoma (MONDO:0003223) is a disease and 1 clinical trial. Top therapeutic interventions include aldesleukin. A subtype of hemangiopericytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	meninges hemangiopericytoma
Mondo ID	MONDO:0003223
DOID	DOID:4957
NCIT	C4660
SNOMED CT	277522009
UMLS	C0349622
MedGen	83894
GARD	0023413
Anatomy (UBERON)	UBERON:0010743
Is cancer (heuristic)	no

Also known as: hemangiopericytoma of meninges · hemangiopericytoma of the central nervous system · hemangiopericytoma of the meninges · meningeal cluster hemangiopericytoma · meningeal cluster spindle cell tumor · meningeal cluster spindle cell tumour · meningeal hemangiopericytoma · meningeal solitary fibrous tumor/hemangiopericytoma · meninges hemangiopericytoma

Disease family

This is a subtype of hemangiopericytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › meninges hemangiopericytoma

Related subtypes (7): kidney hemangiopericytoma, breast hemangiopericytoma, retroperitoneal hemangiopericytoma, heart malignant hemangiopericytoma, adult intracranial malignant hemangiopericytoma, hemangiopericytoma, malignant, hemangiopericytoma of skin

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01082926	PHASE1	COMPLETED	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALDESLEUKIN	4	1